作为抗癌和COX-2抑制剂的新型青混合物:合成,生物评估和对接研究
Mohammad Mahboob Alam1, Nawaf I Alsenani1, Antar A Abdelhamid1,2
1Department of Chemistry, Faculty of Science, Al-Baha University, Al-Baha, Kingdom of Saudi Arabia.
Archiv der Pharmazie
|October 26, 2023
概括
化学修饰的类醇衍生物显示出作为抗癌剂的前景. 化合物11有效地抑制了癌细胞生长和循环氧化酶-2 (COX-2) 活性,这表明了新的治疗途径.
科学领域:
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
- 癌症生物学 癌症生物学
背景情况:
- 药物再利用为开发新疗法提供了一个可行的策略.
- ,一种常见的止痛药和抗发烧药,经过化学修改,以探索其在癌症治疗中的潜力.
- 循环氧化原酶-2 (COX-2) 是癌症治疗中验证的标.
研究的目的:
- 为了合成和评估新型青醇衍生物作为潜在的抗癌和抗COX-2药物.
- 确定最强大的衍生品并阐明其作用机制.
- 为了评估合成化合物的 in silico 药理动力学特性.
主要方法:
- 降醇衍生物的化学合成.
- 在体外细胞毒性测定对癌症细胞系.
- 对COX-2活性进行酶抑制测定.
- 细胞周期和细胞亡分析.
- 分子对接和in silico药理动力学预测.
主要成果:
- 化合物11是一种替代的胺衍生物,表现出显著的细胞毒性作用 (IC50: 1.516.31 μM) 和强烈的抗COX-2活性 (IC50: 0.29 μM).
- 化合物11诱导了Huh-7结肠癌细胞中的S相细胞周期停止和细胞亡.
- 接研究显示,与COX-2活性部位残留物发生了有利的相互作用,而in silico预测表明了良好的药物动力学特征.
结论:
- 化合物11通过阻断COX-2酶阻断抑制细胞增殖,显示出作为抗癌剂的显著潜力.
- 合成的偏醇衍生物需要进一步研究癌症治疗.
- 这项研究突出了药物重新定位和化学修饰在新药发现中的成功应用.
相关概念视频
Structure-Activity Relationships and Drug Design
735
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
735
Combined Effects of Drugs: Synergism
4.0K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
4.0K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Mutagenicity and Carcinogenicity
1.3K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.3K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
170
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
170
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
287
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
287


